XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1

Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Apr. 30, 2006	Jun. 30, 2005	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenue			$ 60,827,000	$ 38,429,000
Deferred Revenue			4,744,000		$ 15,857,000
Drug Product Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenue			7,594,000	8,480,000
Japan [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price, variable consideration from estimated future co-development billing			0
Japan [Member] | Drug Product Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenue			9,800,000
Europe [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price, variable consideration from estimated future co-development billing			$ 14,600,000
Astellas Agreement [Member] | Japan [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received		$ 172,600,000
Additional consideration based on net sales description			the low 20% range of the list price
Aggregate consideration received excluding drug product revenue			$ 105,100,000
Revenue resulting from changes to estimated variable consideration			0
Astellas Agreement [Member] | Japan [Member] | Drug Product Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenue			$ 7,600,000	4,000,000.0
Astellas Agreement [Member] | Europe [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received	$ 745,000,000.0
Additional consideration based on net sales description			low 20% range
Aggregate consideration received excluding drug product revenue			$ 660,000,000.0
Total revenue			0	$ 0
Percentage of joint development costs committed to fund	50.00%
Transaction price and allocated to performance obligations			25,000,000.0
Changes in revenue from changes to estimated variable consideration			$ 25,000,000.0

X

- Definition

The amount of additional consideration based on net sales of product as defined under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.

+ References

No definition available.

+ Details

Name:	fgen_PercentageOfFundingForCosts
Namespace Prefix:	fgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Revenue resulting from changes to estimated variable consideration.

+ References

No definition available.

+ Details

Name:	fgen_RevenueResultingFromChangesToEstimatedVariableConsideration
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Transaction price allocated to performance obligations.

+ References

No definition available.

+ Details

Name:	fgen_TransactionPriceAllocatedToPerformanceObligations
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Variable consideration payment received from estimated future co-development billing.

+ References

No definition available.

+ Details

Name:	fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: